Fatemeh Kazemi-Lomedasht

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 20

Top Venues

Current protein & peptide science

Current pharmaceutical design

Current pharmaceutical biotechnology

Immunopharmacology and immunotoxicology

Pasteur Institute of Iran

Pasteur Institute of Iran (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Pasteur Institute of Iran Jul 04 2015

Iran

Assistant Professor :: Medical Biotechnology

Education History

Pasteur Institute of Iran Feb 20 2011 - May 19 2015

Iran

PHD :: Medical Biotechnology

Publications

Mohammad Hosseininejad Chafi, Mohsen Eslamnezhad-Namin, Mansoureh Shahbazi Dastjerdeh, Mohammad Reza Zareinejad, Akbar Oghalaie, Kamran Pooshang Bagheri, Fatemeh Kazemi-Lomedasht, Gholamreza Karimi, Mehdi Razzaghi-Abyaneh, Sima Sadat Seyedjavadi, Mahdi Behdani
CTXP, The Major Cobra Toxin Peptide from Naja Naja Oxiana Venom; A Promising Target for Antivenom Agent Development. Current protein & peptide science 25 (6) (2024)
Mohammad Hosseininejad Chafi, Mohsen Eslamnezhad-Namin, Mansoureh Shahbazi Dastjerdeh, Mohammad Reza Zareinejad, Akbar Oghalaie, Kamran Pooshang Bagheri, Fatemeh Kazemi-Lomedasht, Gholamreza Karimi, Mehdi Razzaghi-Abyaneh, Sima Sadat Seyedjavadi, Mahdi Behdani
CTXP, The Major Cobra Toxin Peptide From Naja Naja Oxiana Venom; A Promising Target for Antivenom Agent Development. Current protein & peptide science (2024)
Fatemeh Kazemi-Lomedasht, Farzad Taghizadeh-Hesary, Zahra Faal, Mahdi Behdani
Targeted Delivery of Diphtheria Toxin into VEGFR1/VEGFR2 Overexpressing Cells Induces Anti-angiogenesis Activity. Current protein & peptide science 25 (7) (2024)
Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, Zohre Eftekhari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology. Medical oncology (Northwood, London, England) 41 (10) (2024)
Ali Takhteh, Mohammad Hosseininejad-Chafi, Akbar Oghalaie, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Development and Characterization of an Anti-PD-L1 Immunotoxin for Targeted Cancer Therapy. Current pharmaceutical biotechnology (2024)
Mohammad Hosseininejad Chafi, Mohsen Eslamnezhad-Namin, Mansoureh Shahbazi Dastjerdeh, Mohammad Reza Zareinejad, Akbar Oghalaie, Kamran Pooshang Bagheri, Fatemeh Kazemi-Lomedasht, Gholamreza Karimi, Mehdi Razzaghi-Abyaneh, Sima Sadat Seyedjavadi, Mahdi Behdani
CTXP, The Major Cobra Toxin Peptide from Naja Naja Oxiana Venom; A Promising Target for Antivenom Agent Development. Current protein & peptide science 25 (6) (2024)
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line. Current pharmaceutical design (2024)
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line. Current pharmaceutical design 30 (17) (2024)
Nastaran Vahabi Barzi, Delaram Doroud, Maryam Tajabadi-Ebrahimi, Fatemeh Kazemi-Lomedasht
Improving Vaccine Response through Probiotics and Micronutrient Supplementation: Evaluating the Role of TLR5 in Adult Female BALB/c Mice. Current pharmaceutical design (2024)
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line. Current pharmaceutical design 30 (17) (2024)
Elmira Karami, Maryam Mesbahi Moghaddam, Fatemeh Kazemi-Lomedasht
Use of Albumin for Drug Delivery as a Diagnostic and Therapeutic Tool. Current pharmaceutical biotechnology (2023)
Reyhaneh Roshan, Shamsi Naderi, Mahdi Behdani, Reza Ahangari Cohan, Fatemeh Kazemi-Lomedasht
A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin. Molecular biotechnology (2022)
Ayda Hassanzadeh Eskafi, Akbar Oghalaei, Fereidoun Mahboudi, Hajarsadat Ghaderi, Mahdi Behdani, Alireza Shoari, Fatemeh Kazemi-Lomedasht
Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. Immunopharmacology and immunotoxicology (2022)
Elmira Karami, Maryam Mesbahi Moghaddam, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes. Preparative biochemistry & biotechnology (2022)
Elmira Karami, Shamsi Naderi, Reyhaneh Roshan, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies. Cancer chemotherapy and pharmacology 89 (2) (2022)
Shamsi Naderi, Reyhaneh Roshan, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin. Immunopharmacology and immunotoxicology 43 (2) (2021)
Farnaz Khodabakhsh, Serge Muyldermans, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors. Journal of drug targeting 28 (4) (2019)
Amir Sadeghi, Mahdi Behdani, Serge Muyldermans, Mahdi Habibi-Anbouhi, Fatemeh Kazemi-Lomedasht
Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. Drug testing and analysis 12 (1) (2019)
Farnaz Khodabakhsh, Mahdi Behdani, Abbas Rami, Fatemeh Kazemi-Lomedasht
Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies. International reviews of immunology 37 (6) (2019)
Mehrdad Ahadi, Haniyeh Ghasemian, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. Journal of immunotoxicology 16 (1) (2018)

Fatemeh Kazemi-Lomedasht.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Fatemeh Kazemi-Lomedasht